A randomized, double-blind, placebo-controlled phase II study of testosterone replacement in men with asymptomatic castrate-resistant prostate cancer (PC).

Faculty Opinions recommendation of Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.714997807.790402828 ◽

2012 ◽

Author(s):

Hendrik van Poppel ◽

Yuri Tolkach

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

A phase II study of docetaxel plus lycopene in metastatic castrate resistant prostate cancer

Biomedicine & Pharmacotherapy ◽

10.1016/j.biopha.2021.112226 ◽

2021 ◽

Vol 143 ◽

pp. 112226

Author(s):

Eric Zhuang ◽

Edward Uchio ◽

Michael Lilly ◽

Xiaolin Zi ◽

John P. Fruehauf

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Phase II study of cabazitaxel with or without abiraterone acetate and prednisone in patients with metastatic castrate resistant prostate cancer after prior docetaxel and abiraterone acetate

Annals of Oncology ◽

10.1093/annonc/mdw674 ◽

2017 ◽

Vol 28 (3) ◽

pp. 668 ◽

Cited By ~ 1

Author(s):

E.R. Kessler ◽

D. Gao ◽

T.W. Flaig ◽

K. Breaker ◽

M. Wold ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Abiraterone Acetate ◽

Safety and efficacy of sorafenib in patients with castrate resistant prostate cancer: A Phase II study

Urologic Oncology Seminars and Original Investigations ◽

10.1016/j.urolonc.2008.06.003 ◽

2010 ◽

Vol 28 (1) ◽

pp. 21-27 ◽

Cited By ~ 24

Author(s):

Mohammad Reza Safarinejad

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Safety And Efficacy ◽

674 DELAYED PSA RESPONSES IN PERSONALIZED PEPTIDE VACCINATION FOR CASTRATE-RESISTANT PROSTATE CANCER PATIENTS PHASE II STUDY

The Journal of Urology ◽

10.1016/j.juro.2012.02.756 ◽

2012 ◽

Vol 187 (4S) ◽

Author(s):

Masanori Noguchi ◽

Fukuko Moriya ◽

Shigetaka Suekane ◽

Kei Matsuoka ◽

Satoko Matsueda ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Peptide Vaccination ◽

The extended/phase II study of safety and tolerability of proxalutamide (GT0918) in subjects with metastatic castrate resistant prostate cancer (mCRPC) who failed either abiraterone (Abi) or enzalutamide (Enza)

Annals of Oncology ◽

10.1093/annonc/mdz248.055 ◽

2019 ◽

Vol 30 ◽

pp. v355 ◽

Cited By ~ 1

Author(s):

N.J. Vogelzang ◽

N. Gabrail ◽

Z. Malik ◽

F. Volterra ◽

L.T. Nordquist ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Extended Phase ◽

A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC)

Investigational New Drugs ◽

10.1007/s10637-010-9455-x ◽

2010 ◽

Vol 29 (6) ◽

pp. 1465-1474 ◽

Cited By ~ 49

Author(s):

Michael R. Harrison ◽

Noah M. Hahn ◽

Roberto Pili ◽

William K. Oh ◽

Hans Hammers ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

7014 A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive Castrate Resistant Prostate Cancer (CRPC)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)71392-8 ◽

2009 ◽

Vol 7 (2) ◽

pp. 410

Author(s):

E.K. Beardsley ◽

S.J. Hotte ◽

S. Ellard ◽

E. Winquist ◽

S. North ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer

Investigational New Drugs ◽

10.1007/s10637-013-9940-0 ◽

2013 ◽

Vol 31 (4) ◽

pp. 1044-1050 ◽

Cited By ~ 8

Author(s):

Robert Dreicer ◽

Jorge Garcia ◽

Brian Rini ◽

Nicholas Vogelzang ◽

Sandy Srinivas ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Metastatic Prostate Cancer ◽

Phase Ii Study ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant

Overall survival (OS) analysis of a phase II study using a pox viral-based vaccine, PSA-TRICOM, in the treatment of metastatic, castrate-resistant prostate cancer (mCRPC): Implications for clinical trial design

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.3005 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 3005-3005 ◽

Cited By ~ 4

Author(s):

R. A. Madan ◽

J. L. Gulley ◽

W. L. Dahut ◽

K. Y. Tsang ◽

S. M. Steinberg ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Trial ◽

Overall Survival ◽

Phase Ii ◽

Trial Design ◽

Phase Ii Study ◽

Clinical Trial Design ◽